LP
SLNO

LMR Partners’s Soleno Therapeutics SLNO Stock Holding History

LMR Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,830
Closed -$292K – 1290
2024
Q1 		$292K Buy
+6,830
New +$309K ﹤0.01% 823
2021
Q3 		– Sell
-1,300
Closed -$22K – 1173
2021
Q2 		$22K Buy
+1,300
New +$22K ﹤0.01% 1070

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

LMR Partners's SLNO Position: Q2 2024 in Review

LMR Partners sold out of Soleno Therapeutics (SLNO) in Q2 2024, closing a stake of 6,830 shares — an estimated $292K sold.

LMR Partners first reported a position in SLNO in Q2 2021 and held it in 2 quarters. The position peaked at $292K in Q1 2024. 114 funds tracked by Wall St. Rank hold SLNO as of Q2 2024.

  • LMR Partners reported no remaining Soleno Therapeutics position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 6,830 Soleno Therapeutics shares in Q2 2024, an estimated $292K.
  • LMR Partners first reported a position in Soleno Therapeutics in Q2 2021 and held it in 2 quarters.
  • LMR Partners's Soleno Therapeutics position peaked at $292K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.